Sotac Pharmaceuticals

Sotac Pharmaceuticals Receivables Turnover

The Receivables Turnover Ratio of Sotac Pharmaceuticals (SOTAC.NS) as of Nov 16, 2026 is 2.84. In the previous year, Receivables Turnover Ratio was 5.97 — a change of -52.38% (lower).

Receivables Turnover

2.84

YoY

-52.38%

Last updated:

Receivables Turnover Ratio of Sotac Pharmaceuticals is 2025 2.84 . Receivables Turnover Ratio of Sotac Pharmaceuticals was 2024 5.97 . It decreases by -52.38% lower compared to the previous year.

The Sotac Pharmaceuticals Receivables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables Turnover
Date
Receivables Turnover
Jan 1, 2020
4.11 INR
Jan 1, 2021
8.30 INR
Jan 1, 2022
5.97 INR
Jan 1, 2025
2.84 INR
The Sotac Pharmaceuticals Receivables Turnover history
YEARReceivables TurnoverYoY
2.84-52.38%
5.97-28.07%
8.30+101.97%
4.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

Receivables Turnover Ratio of Sotac Pharmaceuticals is 2.84 in 2025.

Receivables Turnover Ratio of Sotac Pharmaceuticals changed from 5.97 to 2.84, representing a -52.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Receivables Turnover Ratio Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Receivables turnover measures how efficiently a company collects its receivables. Higher turnover indicates faster collection.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables Turnover Ratio's Sotac Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Sotac Pharmaceuticals

All Key Metrics — Sotac Pharmaceuticals